CAMBRIDGE, UK– 26 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Mitochondria-Targeted Drug Development Digital Summit (27-29 April).
Paul will present a seminar titled: USP30 Inhibitors: Releasing the Brakes to Improve Mitochondrial Quality Control During Disease, on 28 April at 14:15 EST / 20.15 CEST. He will explore multiple disease pathologies and detail how they can be prevented by inhibiting Mission Therapeutics’ in-house DUB target, USP30.
The Mitochondria-Targeted Drug Development Digital Summit is an industry-led meeting focused on end-to-end mitochondria targeting. The virtual event will be attended by over 80 senior CSOs, CEOs, research scientists, academics and investors, who share a commitment to tackling mitochondrial and age-related diseases. Over the three days, a series of presentations, workshops and networking sessions will focus on success stories, common obstacles, and opportunities in the field of mitochondria-targeted drug development.
– ENDS –
FOR MORE INFORMATION:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340
Melanie Toyne-Sewell / Katie Duffell
Tel: +44 (0) 20 7457 2013
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.
To date the Company has received £73 million /$101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.